Study of Pyridoglutethimide in Postmenopausal Breast Cancer Patients
Author Information
Author(s): M. Dowsett, F. MacNeill, A. Mehtal, C. Newton, B. Haynes, A. Jones, M. Jarman, P. Lonning, T.J. Powles, R.C. Coombess
Primary Institution: Royal Marsden Hospital
Hypothesis
Does pyridoglutethimide suppress estrogen levels and have dose-related toxicity in postmenopausal breast cancer patients?
Conclusion
Pyridoglutethimide effectively suppresses estrogen levels at a dose of 200 mg twice daily, with limited side effects compared to other treatments.
Supporting Evidence
- Plasma levels of oestradiol were significantly suppressed by the lowest dose of PyG.
- One patient showed an objective response to treatment.
- Side effects included nausea and lethargy, with some patients withdrawing from the study.
Takeaway
This study tested a new medicine called pyridoglutethimide to see if it can lower estrogen levels in women with breast cancer after menopause. It worked well at a low dose without causing too many problems.
Methodology
Ten postmenopausal breast cancer patients were given four different doses of pyridoglutethimide over a period of 2 weeks each, and their hormone levels were monitored.
Potential Biases
Potential bias due to the small number of participants and the lack of a control group.
Limitations
The small sample size limits the ability to generalize the findings, and the study may not have captured all potential side effects.
Participant Demographics
All participants were postmenopausal women with advanced metastatic breast cancer.
Statistical Information
P-Value
0.0001
Confidence Interval
95%
Statistical Significance
p<0.0001
Want to read the original?
Access the complete publication on the publisher's website